RICHARD D. PEARSON, M.D.; ERIK L. HEWLETT, M.D.
This content is PDF only. Please click on the PDF icon to access.
Niclosamide [N-(2′-chloro-4′-nitrophenyl)-5-chlorosalicylamide] was developed at Bayer A. G. (1-3) and initially shown to be effective against Hymenolepis diminuta, the rat tapeworm, a cestode that occasionally infects humans. Subsequent studies in animals and humans showed that niclosamide was poorly absorbed and non-toxic after oral administration (2) and that it was active against a number of tapeworms that infect humans. Niclosamide is also used in veterinary practices and as a molluscicide.
Niclosamide first became commercially available outside the United States in 1961 (Yomesan; Bayer A.G., Wuppertal, West Germany), but until recently it could be obtained in this country only as an investigational
PEARSON RD, HEWLETT EL. Niclosamide Therapy for Tapeworm Infections. Ann Intern Med. ;102:550–551. doi: 10.7326/0003-4819-102-4-550
Download citation file:
Published: Ann Intern Med. 1985;102(4):550-551.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use